Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Intellia Therapeutics Inc Stock Research

NTLA

33.10USD-0.89(-2.62%)Delayedas of 21 Sep 2023, 12:36 pm
Watchlist

Market Summary

USD33.10-0.89
Delayedas of 21 Sep 2023, 12:36 pm
-2.62%

NTLA Alerts

  • Losses in recent quarter

NTLA Stock Price

NTLA RSI Chart

NTLA Valuation

Market Cap

3.0B

Price/Earnings (Trailing)

-6.62

Price/Sales (Trailing)

56.62

Price/Free Cashflow

-7.81

NTLA Price/Sales (Trailing)

NTLA Profitability

Return on Equity

-36.15%

Return on Assets

-30.36%

Free Cashflow Yield

-12.8%

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

53.0M

Revenue Y/Y

-3.11%

Revenue Q/Q

7.84%

NTLA Earnings

Earnings (TTM)

-453.4M

Earnings Y/Y

-22.85%

Earnings Q/Q

-19.93%

Price Action

52 Week Range

32.4463.12
(Low)(High)

Last 7 days

-4.2%

Last 30 days

-10.1%

Last 90 days

-19.0%

Trailing 12 Months

-45.6%

NTLA Financial Health

Current Ratio

9.32

NTLA Investor Care

Shares Dilution (1Y)

16.52%

Diluted EPS (TTM)

-5.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for NTLA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-07-31
Bhanji Muna
sold
-11,217
42.33
-265
-
2023-07-06
Bhanji Muna
sold
-73,373
39.3
-1,867
-
2023-07-03
Clark Eliana
sold
-14,583
40.51
-360
evp, chief technical officer
2023-06-20
Clark Eliana
acquired
61,350
12.27
5,000
evp, chief technical officer
2023-06-20
Clark Eliana
sold
-225,000
45.00
-5,000
evp, chief technical officer
2023-06-14
CHASE WILLIAM J
acquired
-
-
1,673
-
2023-06-14
Crowley John F
acquired
-
-
4,425
-
2023-06-14
Bhanji Muna
acquired
-
-
4,425
-
2023-06-14
GOODMAN JESSE
acquired
-
-
4,425
-
2023-06-14
Keresty Georgia
acquired
-
-
4,425
-

1–10 of 50

Which funds bought or sold NTLA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-12
Farther Finance Advisors, LLC
unchanged
-
63.00
734
-%
2023-09-07
Triatomic Management LP
sold off
-100
-372,700
-
-%
2023-09-06
Deep Track Capital, LP
added
18.58
7,811,540
34,069,500
1.58%
2023-09-01
Orchard Capital Management, LLC
new
-
6,490,340
6,490,340
2.18%
2023-08-23
WOLVERINE TRADING, LLC
new
-
264,541
264,541
-%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
24.64
93,545
350,708
-%
2023-08-21
VitalStone Financial, LLC
new
-
-
-
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
6.45
571,299
4,039,420
0.01%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-6.2
23,176
817,639
-%
2023-08-16
Nuveen Asset Management, LLC
reduced
-52.63
-18,999,900
20,440,100
0.01%

1–10 of 47

Latest Funds Activity

Are funds buying NTLA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NTLA
No. of Funds

Schedule 13G FIlings of Intellia Therapeutics

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.28%
7,810,226
SC 13G/A
Jan 25, 2023
blackrock inc.
8.7%
7,254,921
SC 13G
Feb 14, 2022
nikko asset management americas, inc.
3.70%
2,753,903
SC 13G/A
Feb 11, 2022
regeneron pharmaceuticals, inc.
4.98%
3,702,995
SC 13G/A
Feb 09, 2022
ark investment management llc
10.64%
7,916,882
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
3.70%
2,753,903
SC 13G/A
Feb 03, 2022
blackrock inc.
7.6%
5,620,376
SC 13G/A
Nov 26, 2021
ark investment management llc
10.40%
7,642,452
SC 13G/A

Recent SEC filings of Intellia Therapeutics

View All Filings
Date Filed Form Type Document
Aug 03, 2023
10-Q
Quarterly Report
Aug 03, 2023
8-K
Current Report
Aug 02, 2023
4
Insider Trading
Jul 31, 2023
144
Notice of Insider Sale Intent
Jul 10, 2023
4
Insider Trading
Jul 06, 2023
144
Notice of Insider Sale Intent
Jul 06, 2023
4
Insider Trading
Jun 22, 2023
4
Insider Trading
Jun 20, 2023
144
Notice of Insider Sale Intent
Jun 16, 2023
8-K
Current Report

Peers (Alternatives to Intellia Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
271.4B
56.0B
2.30% 9.45%
31.25
4.84
-2.31% -31.27%
265.4B
1.8B
-1.67% 25.43%
-153.19
146.56
69.45% 14.65%
90.8B
9.5B
0.45% 22.78%
26.99
9.56
13.83% 5.33%
89.0B
12.7B
-1.51% 18.09%
20.7
7.02
-10.94% -24.40%
21.9B
1.2B
-7.00% -17.21%
-20.61
17.72
39.94% -8.44%
11.0B
1.0B
3.70% 3.57%
-12.12
10.97
20.15% -79.16%
10.5B
2.1B
-3.12% 8.08%
12.05
4.98
18.01% 38.16%
MID-CAP
3.1B
225.6M
0.04% -28.00%
-5.53
13.59
-2.11% 21.02%
3.0B
-
-10.01% 147.80%
-9.03
-
- -28.88%
2.6B
402.9M
-2.14% -20.15%
-3.59
6.42
20.50% -42.46%
1.9B
27.2M
-14.18% -57.07%
-2.57
69.63
- -14.43%
SMALL-CAP
3.1B
-
-2.94% -39.70%
-7.31
33.28
34.30% -149.91%
1.3B
302.9M
-16.58% -4.84%
11.23
4.28
77.72% 112.02%
281.2M
152.5M
-11.67% 38.41%
37.75
1.84
127.84% 103.41%
29.9M
-
1.35% 3552.08%
-0.65
-
- -31.51%

Intellia Therapeutics News

Nasdaq
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to ....
Nasdaq,
2 days ago
The Motley Fool
Morningstar.ca
Yahoo Finance
The Motley Fool
The Motley Fool
InvestorPlace

Returns for NTLA

Cumulative Returns on NTLA

8.9%


7-Year Cumulative Returns

4.9%


5-Year Cumulative Returns

13.1%


3-Year Cumulative Returns

Risks for NTLA

What is the probability of a big loss on NTLA?

100%


Probability that Intellia Therapeutics stock will be more than 20% underwater in next one year

95%


Probability that Intellia Therapeutics stock will be more than 30% underwater in next one year.

71.5%


Probability that Intellia Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NTLA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Intellia Therapeutics was unfortunately bought at previous high price.

Drawdowns

Financials for Intellia Therapeutics

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-0.8%53,039,00053,475,00052,121,00051,402,00045,340,00037,860,00033,053,00026,794,00041,810,00051,523,00057,994,00062,335,00050,731,00045,586,00043,103,00040,047,00036,839,00033,398,00030,434,00029,222,00029,131,000
  S&GA Expenses8.9%103,871,00095,351,00090,306,00088,788,00085,354,00079,905,00071,096,00059,751,00051,606,00046,449,00044,169,00042,382,00040,247,00041,839,00041,058,00040,790,00040,629,00035,316,00032,189,00033,694,00031,135,000
  R&D Expenses6.5%409,077,000384,000,000419,979,000391,106,000354,941,000323,626,000229,807,000196,877,000176,147,000155,034,000150,408,000143,908,000131,665,000119,354,000108,413,00096,600,00092,324,00090,331,00089,115,00090,367,00084,611,000
EBITDA--------60,652,000-60,941,000-61,125,000-61,193,000-61,243,000-61,255,000-61,474,000-61,701,000-61,943,000-62,295,000-62,526,000-62,792,000---
EBITDA Margin--------1.83-2.27-1.46-1.19-1.06-0.98-1.21-1.35-1.44-1.56-1.70-1.88---
EBT Margin--------2.04-2.52-1.62-1.31-1.16-1.08-1.33-1.48-1.57-1.69-1.83-2.02---
Net Income-5.3%-453,443,000-430,440,000-474,186,000-442,016,000-400,431,000-368,559,000-267,892,000-228,847,000-185,043,000-148,630,000-134,231,000-120,315,000-116,109,000-109,399,000-99,533,000-90,323,000-89,391,000-85,927,000-85,343,000-90,240,000-82,894,000
Net Income Margin100.0%--8.05-9.10-8.60-8.83-9.73-8.10-8.54-4.43-2.88-2.31-1.93-2.29-2.40-2.31------
Free Cashflow100.0%--378,775,000-346,845,000-310,583,000-297,380,000-264,228,000-237,786,000-221,499,000-181,195,000-68,895,000-53,497,000-43,499,000-41,439,000-126,438,000-110,034,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-6.7%1,3231,4181,5201,0841,1101,2031,2941,335672717676459491315334347352344347321340
  Current Assets-2.5%9409641,217859895875769815549601617416446270289296307304325299318
    Cash Equivalents-41.6%17229452414114813312333513014216018036281.0057.0038.0049.0047.0059.00293306
  Net PPE5.0%33.0032.0028.0027.0026.0024.0021.0020.0019.0016.0016.0016.0016.0017.0018.0017.0017.0017.0017.0017.0017.00
  Current Liabilities-3.4%10010312713112412612698.0074.0061.0064.0056.0059.0035.0036.0038.0038.0039.0041.0026.0025.00
Shareholder's Equity-7.2%1,1051,1911,2368258819541,0401,107495546527330352248270276277264278263279
  Retained Earnings-9.7%-1,403-1,280-1,177-1,063-950-849-703-621-550-481-435-392-365-332-300-272-248-223-201-181-159
  Additional Paid-In Capital1.6%2,5132,4742,4201,8981,8411,8121,7461,7291,0451,027962723717580570548526488479445439
Shares Outstanding0.3%88.0088.0087.0077.0076.0075.0074.0074.0068.0067.0066.0054.0052.0050.0050.0049.0046.0045.0043.0043.0043.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-1.4%-368-362-333-298-284-252-225-210-174-63.74-49.91-38.35-35.24-120-103-83.12-70.12-64.94-61.26-74.03-78.46
  Share Based Compensation13.3%11310091.0081.0072.0059.0047.0038.0028.0022.0020.0017.0015.0015.0015.0016.0017.0018.0017.0020.0019.00
Cashflow From Investing-1380.0%-139-9.4116031.00-415-477-550-602-357-297-21424.0014777.0025.00-258-229-253-260-7.16-7.41
Cashflow From Financing-0.6%53453858379.0072472573796930042637215720377.0076.0087.0043.0037.0040.00152150

NTLA Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Collaboration revenue$ 13,594$ 14,030$ 26,200$ 25,282
Type of Revenue [Extensible List]us-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMemberus-gaap:LicenseAndServiceMember
Operating expenses:    
Research and development$ 115,276$ 90,199$ 212,392$ 223,294
General and administrative30,65222,13258,10044,535
Total operating expenses145,928112,331270,492267,829
Operating loss(132,334)(98,301)(244,292)(242,547)
Other income (expense), net:    
Interest income12,65370324,6331,243
Loss from equity method investment(4,000)(3,252)(7,048)(5,997)
Change in fair value of contingent consideration0172(100)(249)
Total other income (expense), net8,653(2,377)17,485(5,003)
Net loss$ (123,681)$ (100,678)$ (226,807)$ (247,550)
Net loss per share, basic$ (1.4)$ (1.33)$ (2.58)$ (3.29)
Net loss per share, diluted$ (1.4)$ (1.33)$ (2.58)$ (3.29)
Weighted average shares outstanding, basic88,18575,82387,97975,282
Weighted average shares outstanding, diluted88,18575,82387,97975,282
Other comprehensive loss:    
Unrealized (loss) gain on marketable securities$ (1,482)$ (932)$ 1,507$ (6,060)
Other comprehensive gain (loss) from equity method investment292(560)2,086(862)
Comprehensive loss$ (124,871)$ (102,170)$ (223,214)$ (254,472)

NTLA Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current Assets:  
Cash and cash equivalents$ 171,806$ 523,506
Marketable securities736,268669,116
Accounts receivable ($0 and $0.3 million, respectively, from related party)5,0563,768
Prepaid expenses and other current assets26,48520,407
Total current assets939,6151,216,797
Marketable securities - noncurrent164,01369,338
Property and equipment, net33,19427,921
Operating lease right-of-use assets123,550133,076
Equity method investment21,83732,455
Investments and other assets41,03140,527
Total Assets1,323,2401,520,114
Current Liabilities:  
Accounts payable11,6345,154
Accrued expenses ($1.4 million and $1.6 million, respectively, from related party)49,53460,876
Current portion of operating lease liability16,75016,685
Current portion of deferred revenue ($2.9 million and $19.9 million, respectively, from related party)21,93343,839
Total current liabilities99,851126,554
Deferred revenue, net of current portion12,91919,932
Long-term operating lease liability105,582114,018
Contingent consideration liability024,026
Commitments and contingencies (Note 6)
Stockholders’ Equity:  
Common stock, $0.0001 par value; 240,000,000 and 120,000,000 shares authorized at June 30, 2023 and December 31, 2022, respectively; 88,347,634 and 87,103,007 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively99
Additional paid-in capital2,512,7412,420,223
Accumulated other comprehensive loss(3,868)(7,461)
Accumulated deficit(1,403,994)(1,177,187)
Total stockholders’ equity1,104,8881,235,584
Total Liabilities and Stockholders’ Equity$ 1,323,240$ 1,520,114
John M. Leonard
480
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.